---
title: "Analyst Initiates Buy Rating on Caris, Highlighting Caris Detect Launch and Early Positive Economics"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291560342.md"
description: "Goldman Sachs analyst Evie Koslosky maintained a Buy rating on Caris Life Sciences with a $27 price target, citing the launch of Caris Detect, a multi-cancer early detection test. The analyst highlighted strong clinical data from the Achieve 1 study and favorable initial gross margins at the $3,500 list price. Additionally, BTIG reiterated a Buy rating with a $32 target, reflecting positive sentiment on the company's commercial expansion and earnings potential."
datetime: "2026-07-02T13:25:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291560342.md)
  - [en](https://longbridge.com/en/news/291560342.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291560342.md)
generator: "portal-rs"
---

# Analyst Initiates Buy Rating on Caris, Highlighting Caris Detect Launch and Early Positive Economics

Caris Life Sciences, Inc., the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evie Koslosky from Goldman Sachs maintained a Buy rating on the stock and has a $27.00 price target.

### 4th of July Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Evie Koslosky has given his Buy rating due to a combination of factors tied to the launch of Caris Detect, a multi-cancer early detection test that leverages whole genome and transcriptome sequencing alongside advanced AI to identify early-stage disease. He views this product as a gateway for Caris to access a substantial new market in multi-cancer early detection, significantly expanding the company’s commercial opportunity.

Koslosky also notes that the test is supported by Achieve 1 study data showing strong specificity and meaningful sensitivity in stage I/II cancers, which underpins clinical credibility as adoption with partners such as Everlywell begins. In addition, the planned $3,500 list price is expected to yield at least neutral gross margins initially, with room for margin improvement as volumes scale, reinforcing his positive outlook on the company’s earnings potential and justifying the Buy recommendation.

In another report released today, BTIG also reiterated a Buy rating on the stock with a $32.00 price target.

### Related Stocks

- [CAI.US](https://longbridge.com/en/quote/CAI.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)

## Related News & Research

- [Caris lassos Kevin Costner for new Caris Detect ad](https://longbridge.com/en/news/298489519.md)
- [Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer | CAI Stock News](https://longbridge.com/en/news/297788849.md)
- [Bispecifics Market to Gain Momentum During the Forecast Period (2026-2036) with Expanding Pipeline and Increasing Therapeutic Adoption | DelveInsight](https://longbridge.com/en/news/298934183.md)
- [EXCLUSIVE-TPG explores $5 billion sale of healthcare software company Lyric, sources say](https://longbridge.com/en/news/298497579.md)
- [AI in Virtual Medical Assistant Market to Reach US$ 12.3 Bn by 2031, Growing at 36.5% CAGR, New Report by Wissen Research](https://longbridge.com/en/news/298618482.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**